News & Events

Read our latest news and explore upcoming events

MOVE TO:

4 May, 2026

The Precision Moonshot: Redefining Cardiovascular Care for 85 Million Europeans

Cardiovascular disease affects 85 million Europeans, yet most patients are still treated as averages rather than individuals. In this article, our leading experts explore how personalised medicine could change that—transforming diagnosis, risk prediction, and treatment. They also unpack the barriers holding progress back, from fragmented data to outdated reimbursement models, and what it will take to bring truly patient-centred care into everyday practice.
Read more

30 April, 2026

The right treatment for the right patient: Rethinking heart failure care

Heart failure is a leading cause of hospitalisation in Europe, especially among..
Read more

29 April, 2026

“Suddenly, you are a patient 24 hours a day” – A patient perspective on living with heart failure

Heart failure affects millions worldwide, yet no two experiences are the same,..
Read more

2 April, 2026

Connecting Health Data for Better Heart Failure Monitoring (SWAT4HCLS conference)

At the SWAT4HCLS conference, iCARE4CVD presented new research introducing the Digital Biomarker..
Read more

15 January, 2026

CMEO: making heart disease and clinical studies easier to find, compare, and reuse

Across Europe, vast amounts of heart disease data already exist—but they are..
Read more

15 January, 2026

Beyond medical results: Using Patient-Reported Outcomes and Experiences in heart care – a scoping review

In a recent scoping review, we examined 390 studies to understand how..
Read more

2 January, 2026

iCARE4CVD salutes the new EU cardiovascular Health Plan!

With the new EU Cardiovascular Health Plan launched – iCARE4CVD welcomes the..
Read more

Subscribe to our newsletter

Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.

Funding acknowledgment

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) and Breakthrough T1D under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe.

Disclaimer

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Quick Links